




RealRate

PHARMACEUTICAL 2023

Pulmatrix Inc.
Rank 168 of 446





RealRate

PHARMACEUTICAL 2023

Pulmatrix Inc.
Rank 168 of 446



The relative strengths and weaknesses of Pulmatrix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pulmatrix Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Pulmatrix Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 93% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	38,147
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,022
Liabilities, Non-Current	0
Other Assets	2,571
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	4,822
Other Net Income	111
Other Revenues	6,071
Property and Equipment	235
Research and Development	18,240
Selling, General and Administrative Expense	6,778

Output Variable	Value in 1000 USD
Assets	40,953
Liabilities	9,844
Expenses	25,018
Revenues	6,071
Stockholders Equity	31,109
Net Income	-18,836
Comprehensive Net Income	-18,836
Economic Capital Ratio	137%